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Abstract C-reactive protein (CRP) has been linked to the
pathogenesis of atherosclerosis. The dissociation of native,
pentameric (p)CRP to monomeric (m)CRP on the cell
membrane of activated platelets has recently been demon-
strated.ThedissociationofpCRPtomCRPmayexplainlocal
pro-inﬂammatory reactions at the site of developing athero-
sclerotic plaques. As a biomarker, pCRP predicts cardio-
vascularadverseeventsandsodoreducedlevelsandfunction
of circulating endothelial progenitor cells (EPCs). We
hypothesisedthat mCRPandpCRPexert a differentialeffect
on EPC function and differentiation. EPCs were treated with
mCRP or pCRP for 72 h, respectively. Phenotypical char-
acterisation was done by ﬂow cytometry and immunoﬂuo-
rescencemicroscopy,whiletheeffectofmCRPandpCRPon
gene expression was examined by whole-genome gene
expression analysis. The functional capacity of EPCs was
determined by colony forming unit (CFU) assay and endo-
thelial tube formation assay. Double staining for acetylated
LDL and ulex lectin signiﬁcantly decreased in cells treated
with pCRP. The length of tubuli in a matrigel assay with
HUVECs decreased signiﬁcantly in response to pCRP, but
not to mCRP. The number of CFUs increased after pCRP
treatment. RNA expression proﬁling demonstrated that
mCRPandpCRPcausehighlycontradictorygeneregulation.
Interferon-responsive genes (IFI44L, IFI44, IFI27, IFI 6,
MX1,OAS2)wereamongthehighlyup-regulatedgenesafter
mCRP, but not after pCRP treatment. In conclusion, EPC
phenotype, genotype and function were differentially affec-
ted by mCRP and pCRP, strongly arguing for differential
roles of these two CRP conformations. The up-regulation of
interferon-inducible genes in response to mCRP may con-
stitute a mechanism for the local regulation of EPC function.
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Introduction
C-reactive protein (CRP) is an acute phase protein that
consists of ﬁve non-covalently linked subunits forming a
disc-shaped pentamer (pCRP) with a molecular weight of
115 kDa. The serum level of pCRP has been established as
an independent risk factor for cardiovascular events [23,
51, 71]. We recently demonstrated the dissociation of
pCRP to monomeric (m)CRP on the cell membrane of
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DOI 10.1007/s00395-011-0191-yactivated platelets and the deposition of mCRP in athero-
sclerotic plaques, thereby suggesting a causal link between
localised inﬂammation, C-reactive protein and atheroscle-
rosis [15, 17]. In addition to our recent ﬁndings, evidence
from other studies points towards a differential effect of
mCRP and pCRP on the activation of platelets and leu-
kocytes [16, 34, 40], which are known key players involved
in the initiation of atherosclerotic plaque development [26].
While elevated serum levels of C-reactive protein are
predictive of adverse cardiovascular events [23, 51, 71],
decreased numbers of circulating endothelial progenitor
cells (EPCs) and impaired function of EPCs have been
described [18, 31, 45, 48, 55, 67, 68], thereby generating
the hypothesis that C-reactive protein might have a nega-
tive effect on EPC number and function. In addition, in
vitro experiments have shown that pCRP reduces the
number of differentiated EPCs along with a reduction in
EPC-mediated endothelial tube formation [64]. Further-
more, a recent study by the same group demonstrated a
dose-dependent increase in pCRP-induced formation of
reactive oxygen species and apoptosis in EPCs [19].
However, the effects of C-reactive protein are versatile
and still not fully understood. It appears that inﬂammation
accompanied by elevated levels of C-reactive protein in
general does not necessarily lead to decreased levels of
circulating EPCs [20, 47]. In fact, the EPC number may
even be elevated [20].
The recent description of the dissociation of pCRP to
mCRP on cell membranes thereby generating two bio-
logically distinct conformations of C-reactive protein [15,
28] prompted us to examine whether mCRP and pCRP
have a differential effect on EPC differentiation and
function.
The term EPC has initially been applied to describe a
cell population possessing the ability to regenerate dam-
aged endothelium and contribute to the development of
new vessel structures (EPC) [3]. Investigations into the
different puriﬁcation and culturing methods have sparked
an ongoing discussion about a more differentiated deﬁni-
tion of these progenitor cells with regenerative capacities
[13, 24, 50, 53, 58, 61, 62, 69]. The new deﬁnition allows a
crude separation into early outgrowth EPC or pro-angio-
genic cells [13] and endothelial outgrowth cells (EOCs)
also described as endothelial colony forming cells (ECFCs)
[24, 61, 69]. The cells that were used in the current study
were derived from CD34
? selected human umbilical cord
blood mononuclear cells. After in vitro expansion, the cells
were differentiated into early outgrowth EPCs [1]. CD34 is
a hematopoietic progenitor cell (HPC) marker, which has
been linked to the term EPC throughout the majority of the
available EPC literature [63, 66]. Therefore, for simpliﬁ-
cation purposes we use the term HPC to describe the
CD34
?-puriﬁed cells and the general term EPC to describe
the cells that were used for the experiments throughout our
study.
CD34
? cells puriﬁed by positive selection from human
cord blood samples were expanded in vitro and thereafter
differentiated into EPCs in the presence or absence of
mCRP or pCRP, respectively. pCRP and mCRP showed
differential effects on survival, differentiation and function
of EPCs. In addition, whole-genome gene expression
analysis revealed a highly differentially and opposing gene
expression pattern in response to treatment with the two
isoforms of CRP. Interferon-responsive genes (IFI44L,
IFI44, IFI27, IFI 6, MX1, OAS2) were among the highly
up-regulated genes in response to mCRP, but not pCRP
treatment of EPCs.
Materials and methods
Isolation and expansion of CD34
? cells
Mononuclear cells (MNCs) were isolated from human
umbilical cord blood (HUCB) obtained from healthy
donors following normal full-term deliveries after their
written informed consent. Ethics approval was granted by
the Human Research Ethics Committee, Mercy Health,
Mercy Hospital for Women, Melbourne, Australia (Project
number R08/24).
HUCB was collected in 50 ml Falcon tubes (BD Bio-
science, NJ, USA) containing 15 ml of the anticoagulant
citrate phosphate dextrose. After collection, HUCB was
diluted 1:3 in isolation buffer (PBS, 0.1% BSA, 0.6% cit-
rate, pH 7.4). MNCs were isolated from the diluted HUCB
by density gradient centrifugation, whereby 20 ml of
diluted HUCB were layered onto 15-ml Ficoll-Paque
TM
(GE Healthcare, Chalfont, UK) and centrifuged for 30 min
at 8009g. Thereafter, the interphase containing MNCs was
collected and washed with an equal amount of isolation
buffer, followed by centrifugation for 30 min at
5009g. The washed MNCs were then subjected to mag-
netic beads-based selection of CD34
? cells using Dynal

CD34 Progenitor Cells Selection System (Invitrogen, Oslo,
Norway) following the manufacturer’s recommendation.
The number of positively selected CD34
? cells, the hae-
matopoietic progenitor cells (HPC), was assessed in a
Neubauer haemocytometer and the purity ([90%) of the
CD34
? cells evaluated by ﬂow cytometry.
The cord blood-derived CD34
? HPCs were cultured at a
density of 3–5 9 10
4 cells/400 ll/1.8 cm
2 in a humidiﬁed
incubator at 37C with 5% CO2. The cells were cultured for
7 days in serum-free StemSpan
 medium (StemCell
Technologies, Vancouver, Canada) during the initial
expansion period and supplemented with 1% penicillin–
streptomycin (Sigma-Aldrich, St. Louis, USA) and
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123recombinant human (rh) Flt-3 ligand (100 ng/ml), rh stem
cell factor (100 ng/ml), rh IL-3 (20 ng/ml) and rh IL-6
(20 ng/ml), all purchased from StemCell Technologies.
Thereafter, the HPCs were cultured (3 9 10
5–1 9 10
6/
1.5 ml/9.6 cm
2) for an additional 3 days in endothelial cell
growth medium-2 (EGM-2) containing FBS (2%), hydro-
cortisone, hFGF, VEGF, R
3-IGF-1, ascorbic acid, hEGF,
gentamicin, amphotericin-B and heparin (Lonza, Basel,
Siwtzerland).
Treatment of EPCs with monomeric and pentameric
CRP
pCRP (Chemicon, Temecula, USA) and mCRP were pre-
pared as described previously [15]. The expanded HPCs
describedabovewerecollectedandtransferredtoﬁbronectin
(10 lg/ml) (Sigma-Aldrich)-coated plates, cultured and
differentiated intoEPCs for3 daysinfresh EGM-2mediain
thepresenceorabsenceofmCRP(1,5or25 lg/ml)orpCRP
(1, 5 or 25 lg/ml), respectively. A control group of HPCs
treated with EGM-2 media containing PBS (diluted 1:40)
was also included.
Cell viability assays
Phosphatidylserine translocation (annexin V binding)
The binding of annexin V to phosphatidylserine was
determined using FITC-conjugated annexin V (BD Bio-
sciences, San Jose, CA, USA). In brief, the EPCs were
washed in annexin-binding buffer (10 mM HEPES,
140 mM NaCl, 2.5 mM CaCl2, pH 7.4) and thereafter
incubated with annexin V-FITC at RT for 15 min. After
additional washing in annexin-binding buffer, the
cells were analysed for annexin V-FITC binding in a
FACSCalibur TM ﬂow cytometer using CellQuest software
(Becton and Dickinson, San Jose, CA, USA). Between
10,000 and 20,000 events per test were acquired. A nega-
tive control with unstained cells was included for each
treatment.
CytoTox-Glo
TM cytotoxicity assay
The relative viability of EPCs treated with mCRP (1, 5, or
25 lg/ml), pCRP (1, 5, or 25 lg/ml) or PBS was analysed
using the CytoTox-Glo
TM cytotoxicity assay (Promega,
Madison, WI, USA) following the manufacturer’s recom-
mendations. In brief, EPCs were added to a 96-well
luminescence plate at a concentration of 10,000 cells/well
in a volume of 100 ll of EGM-2. Thereafter, to detect
protease activity that had been released from dead cells,
50 ll of alanyl-alanyl-phenylalanyl-aminoluciferin lumi-
nogenic peptide substrate (AAF-Glo
TM Substrate) mix was
added to the wells and incubation was carried out for
15 min at RT. The plate was measured in a 96-well plate
luminometer. Immediately after measurement of dead cells
by luminescence, the EPCs were exposed to a lysis buffer
containing digotinin for 15 min at RT and the lumines-
cence was measured again. The number of viable cells was
determined by subtracting the number of dead cells from
the total cell count. A no-cell background control was
included in the assay.
Uptake of acetylated LDL and binding of ulex lectin
To investigate the endothelial progenitor characteristics of
the EPCs, binding of ulex lectin and uptake of Dil-labelled
acetylated LDL (AcLDL) by the cells were analysed by
dual staining of the cells at 37C in PBS.
After expansion, the cells were seeded on a ﬁbronectin-
coated 24-well plate with a density of 3 9 10
5cells/0.5 ml/
1.8 cm
2 and cultured in EGM-2 for 3 days in the presence
or absence of mCRP, pCRP or PBS. Thereafter, cells were
washed twice with PBS at 37C. The cells were then
incubated with Dil-AcLDL (6 lg/ml) (Invitrogen, Carls-
bad, USA) for 1 h at 37C in the dark. Thereafter, the cells
were washed twice with PBS at 37C and incubated with
FITC-conjugated ulex lectin (10 lg/ml) (Sigma-Aldrich,
St. Louis, USA) for 1 h at 37C in the dark. After two ﬁnal
washing steps with PBS at 37C, the cells were ﬁxed with
0.3 ml CellFIX solution (BD Biosciences, NJ, USA), and
subsequently analysed for uptake of Dil-AcLDL and
binding of FITC-ulex lectin using an Olympus 1X81
inverted ﬂuorescence microscope.
The effect of mCRP and pCRP on functional
characteristics of EPCs
The EPCs treated with mCRP or pCRP were studied using
colony forming assay (CFU-Hill) and Matrigel
TM tube
formation assay.
Colony forming unit (CFU) assay
Culture of CFU-Hill colonies (StemCell Technologies) was
performed according to the manufacturer’s recommenda-
tions with the exception that we used ten times less cells
(5 9 10
5 cells/well) and in vitro differentiated cord blood-
derived EPCs instead of freshly prepared MNCs. In brief,
after 72 h of culture on ﬁbronectin in EGM-2 media in the
presence or absence of mCRP or pCRP, the cells were
collected and counted. The collected cells were then cul-
tured (5 9 10
5 cells/1.5 ml/9.6 cm
-2) on ﬁbronectin pre-
coated 6-well plates (BD Biosciences) in EndoCult
 liquid
medium containing EndoCult supplements (StemCell
Technologies). After 2 days, the non-adherent cells were
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123collected and transferred to ﬁbronectin pre-coated 24-well
plates (BD Biosciences) at a density of 3 9 10
5 cells/ml/
1.8 cm
2. After a further 3 days of culture, the cells were
washed twice with PBS, ﬁxed with methanol, and the
colonies were visualised with Giemsa staining (Gibco,
Carslbad, USA), following the manufacturer’s recommen-
dations. The number of colonies per well was counted with
an inverted microscope (Olympus CKX41).
Endothelial tube formation assay
The capability of the mCRP- and pCRP-treated EPCs to
support endothelial tube formation was assessed using
Matrigel
TM (BD Biosciences) coated 96-well plates and
human umbilical vein endothelial cells (HUVECs) in early
passages (P3-P6). In brief, wells of a 96-well plate were
coated with 50 ll of ice-cold Matrigel
TM followed by
incubation at 37C for 1 h. Thereafter, 100 ll of EGM-2
medium containing 25,000 HUVECs and 100 ll of EGM-2
containing 25,000 EPCs were added to the Matrigel
TM.
Incubation was carried out for 16 h in a humidiﬁed atmo-
sphere at 37C in the presence of 5% CO2. Tube formation
was assessed with an inverted microscope (Olympus 1X81)
and Cell^P imaging software (Olympus). Digital photo-
micrographs of each single well were taken at a 49 mag-
niﬁcation and the total number of tubes, branching points,
and the length of the tubes as well as the sum of the lengths
of all tubes were calculated for each well.
Whole-genome gene expression analysis of mCRP
and pCRP-treated EPCs
Total RNA was extracted from 2 9 10
6 EPCs after 72 h of
culture in EGM-2 medium in the presence or absence of
mCRP (1 lg/ml), pCRP (5 lg/ml) or PBS. The RNA was
obtained using Qiagen
 RNeasy protect mini kit
TM fol-
lowing the manufacturer’s instructions. RNA concentration
and integrity was analysed by NanoDrop (Thermo Fischer
Scientiﬁc, Waltham, USA) and MultiNA microchip elec-
trophoresis (Shimadzu Biotech, Kyoto, Japan) according to
the manufacturer’s recommendations. Total RNA was
ampliﬁed with the TotalPrep
TM RNA Ampliﬁcation Kit
(Ambion, UK) and applied to Illumina
 Human WG-6
v3.0 Expression BeadChip kits according to the manufac-
turer’s instructions. Fluorescent bead intensity was trans-
formed into gene expression level via Illumina Genome
Studio, including quantile normalisation [27] and back-
ground subtraction. The exported reports were analysed on
GeneSpring GX10, Partek GS and arraytools (http://linus.
nci.nih.gov/pub/rsimon/ ArrayTools). Genes with a raw
signal \250 and a detection conﬁdence [0.8 in at least
three arrays were ﬁltered out, leaving 6,064 genes for
further analysis. Whisker box plot was used to conﬁrm the
quintile normalisation eliminated systematic cross array
variations in the overall dynamic range. Quality control of
the samples and controlling for systematic bias were per-
formed using principal component analysis and unsuper-
vised hierarchical clustering to show that samples
segregated according to treatment groups. Differentially
expressed genes were selected based on a Bayesian ‘‘vol-
cano plot’’ of expression fold change greater than twofold
and signiﬁcance p value of \0.05, including Benjamini
Hochberg false discovery correction. Differential expres-
sion of the chosen genes across the treatment groups was
assessed using supervised hierarchical clustering [14] that
measures the proximity of distribution of samples and
genes. The interpretation of the resulting gene lists was
performed using gene ontology Web interface (http://david.
abcc.ncifcrf.gov/), Gene Set Analysis [6], protein–protein
interaction KEGG database [22] and Ingenuity Pathways
Analysis [49].
Quantitative real-time PCR analysis
First-strand cDNA was synthesised using 350 ng of total
RNA, obtained as described in the microarray section, and
random primers in a 10 ll reverse transcriptase reaction
mixture using TaqMan
 Reverse Transcription Reagents
(Applied Biosystems) following the manufacturer’s rec-
ommendations. Quantitative real-time PCR assays were
carried out with Applied Biosystems 7500 real-time PCR
system using SYBR Green Mastermix (Applied Biosys-
tems, Carlsbad, USA). Primers were designed in-house and
synthesised by GeneWorks (Hindmarsh, Australia). PCR
ampliﬁcation was performed in a 96-well plate with a ﬁnal
volume of 20 ll reaction mixture in each well. For each
sample, 21 ng of cDNA was loaded in duplicates with 19
SYBR
 Green Mastermix and 10 lM of the following
primers for: Mx1 sense 50-CACTGCGCAGGGACCGGAA
TT-30 and anti-sense 50-TCCTGTAGCCTCCGACCCAGA
A-30; OAS2 sense 50-GCTCCCGGCCCACCAAACTA-30
and anti-sense 50-TGGGGGCAAAGACCCCTTTGG-30;
OAS3 sense 50-GGACCCTGCAGTTGGGCAGT-30 and
anti-sense 50-CCCATGTGGGGTCAGCTGGG-30; IFIT3
sense 50-ACCGGGACCCCAGCTTTTCAG-30 and anti-
sense 50-AGCTGTGGAAGGATTTTCTCCAGGG-30; IFI6
sense 50-TCCGGGCTGAAGATTGCTTCTCTT-30 and
anti-sense 50- ACTTTTTCTTACCTGCCTCCACCCC-30;
IFI44 sense 50-GAGATGTGAGCCTGTGAGGTCCAA-30
andanti-sense50TTTACAGGGTCCAGCTCCCACTCA-30;
IFI27sense50-CCGTAGTTTTGCCCCTGGCC-30 andanti-
sense 50-CATGGGCACAGCCGCCATG-30; IFI44L sense
50- ATGTGACTGGCCAAGCCGTAGT-30 and anti-sense
50TGCCCCATCTAGCCCCATAGTGT-30; PROK2 sense
50-TGGGAGACAGCTGCCATCCAC-30 and anti-sense 50-A
GCCTGGCAGACATGGGCAA30;D D I T 3s e n s e5 0-TC
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123AGAGCTGGAACCTGAGGAGAGA-30 and anti-sense 50-
ATGGGGAGTGGCTGGAACAAGC-30. Relative expres-
sion of the genes was obtained using the differences in cycle
threshold (Ct) between the sample and 18S ribosomal RNA
(DC).Thedifferenceingeneexpressionforthetreatedsamples
compared to the PBS control samples was calculated (DDCt)
and the fold difference was calculated as 2DDCt.
Treatment with human IFNa2A
The expanded HPCs were collected and transferred to
ﬁbronectin (10 lg/ml)-coated plates, cultured and differ-
entiated into EPCs for 3 days in fresh EGM-2 media in the
presence or absence of IFNa2A (0.1–10 ng/ml) (Sigma),
mCRP (1 lg/ml) or pCRP (5 lg/ml), respectively. A con-
trol group of HPCs treated with EGM-2 media containing
PBS (diluted 1:40) was also included. Changes in gene
expression were determined using real-time PCR. In
addition, uptake of AcLDL and binding of ulex lectin, CFU
assay and endothelial tube formation assay were investi-
gated as described above.
Statistical analysis
All experiments were performed with EPCs from at least
three different donors, respectively. Mean and SD were
used for descriptive statistics. Statistical analysis was
performed using Sigma Stat. Differences between means
were assessed by analysis of variance (ANOVA) and post
hoc test was carried out according to Bonferroni. p values
\0.05 were considered to be statistically signiﬁcant.
Results
EPCs were treated with mCRP, pCRP or PBS for a period
of 72 h in ﬁbronectin-coated six-well plates (10 lg/ml).
Thereafter EPC viability, phenotype and function were
assessed. In addition, differences in gene expression pro-
ﬁles were assessed in EPCs derived from three different
cord blood donors before and after mCRP, pCRP and PBS
treatment, respectively.
Assessment of mCRP and pCRP toxicity
The effect of a 72-h treatment period of mCRP and
pCRP on EPC viability was investigated using a cyto-
toxicity luminescence assay. First, the number of dead
cells was measured and secondly the total number of
cells was measured. The relative number of viable cells
(relative live cell luminescence, RLU) obtained in the
assay is demonstrated in Fig. 1a. There was no toxicity
associated with mCRP treatment (1, 5, or 25 lg/ml for
72 h). In fact, mCRP signiﬁcantly (p\0.05–0.001)
increased the viability/cell numbers in a dose-dependent
manner (Fig. 1a). In accordance to mCRP, pCRP at the
concentrations 1 and 5 lg/ml for 72 h was not toxic to
the EPCs. However, at the concentration of 25 lg/ml,
the viability of the cells was strongly reduced
(p\0.001, Fig. 1a). In addition to the luminescence-
based cytotoxicity assay, which is based on protease
activity released from cells through the loss of mem-
brane integrity, the effect of mCRP and pCRP treatment
on EPCs was also determined by annexin V binding. In
accordance with the cytotoxicity assay, only pCRP at the
concentration 25 lg/ml induced an increased binding of
annexin V, thereby indicating a pro-apoptotic/necrotic
effect on EPCs (Fig. 1b).
In the following descriptive and functional investiga-
tions, we focused on the comparison of 1 and 5 lg/ml
mCRP and pCRP, respectively, to adjust for molarity of the
pentameric structure of pCRP.
0
100000
200000
300000
400000
500000
PBS 1 5 25 1 5 25
L
i
v
e
 
C
e
l
l
 
L
u
m
i
n
e
s
c
e
n
c
e
 
(
R
L
U
)
A
***
*
***
***
***
mCRP pCRP
Annexin V
B
Fig. 1 Cytotoxicity assay after 72 h of EPC treatment with mCRP
and pCRP. a Viable cells were measured by the CytoTox-Glo
TM
cytotoxicity assay. The bars represent the relative luminesce unit
(RLU) calculated for the viable cells, i.e. dead cells deducted from
total cells, mean and SD of n = 3. b. Histograms of one represen-
tative experiment showing the binding of the apoptosis marker
Annexin V to EPCs using a FITC-labelled Annexin V antibody
detected by ﬂow cytometry
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123pCRP but not mCRP treatment decreased the number
of AcLDL and ulex lectin double-positive cells
One phenotypic characteristic for EPCs is their ability to
take up AcLDL and to bind ulex lectin. The uptake of
AcLDL and the binding of ulex lectin were investigated by
immunoﬂuorescence staining using Dil-labelled AcLDL
and FITC-labelled ulex lectin. The percentage of cells
double positive for uptake of Dil-labelled AcLDL and
binding of FITC-labelled ulex lectin after treatment with
1 lg/ml mCRP, 5 lg/ml pCRP and PBS was 36 ± 7,
42 ± 11 and 12 ± 3%, respectively (Fig. 2a). The per-
centage of double-positive cells indicating EPC phenotype
was signiﬁcantly decreased after pCRP treatment
(12 ± 3%, p\0.05, Fig. 2a). In contrast, EPCs treated
with mCRP (1 lg/ml) were not affected and showed a
similar percentage of double-positive cells compared to the
PBS control.
Functional characteristics of EPCs are differentially
affected by mCRP and pCRP
EPCs were treated with mCRP (1 lg/ml), pCRP (5 lg/ml)
or PBS and then assessed for their ability to form colony
forming units (CFU-Hill) and to support endothelial tube
formation. Treatment of EPCs with pCRP signiﬁcantly
increased the number of CFUs (40 ± 5, p\0.001),
whereas mCRP (19 ± 2) did not affect the number of
CFUs compared to PBS (25 ± 3) treated cells (Fig. 2b).
The effect of mCRP (1 lg/ml) and pCRP (5 lg/ml) treat-
ment on the ability of EPCs to support formation of
endothelial tubuli in a co-culture with human umbilical
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Fig. 2 The effect of mCRP (1 lg/ml) or pCRP (5 lg/ml) on
phenotype and function of EPCs. a Binding of ulex lectin and uptake
of AcLDL after 72 h of culture of EPCs in the presence or absence of
mCRP or pCRP visualised with FITC-labelled ulex lectin and Dil-
labelled AcLDL, respectively. The photomicrographs show a typical
optical ﬁeld from one representative experiment. The bar graph
shows the percentage of double-positive cells, mean and SD of n = 3.
b The number of colony forming units (CFU-Hill) visualised by
Giemsa staining. The bars represent the total number of colonies per
well in a 24-well plate, mean and SD of n = 3. c Endothelial tube
formation assay after 72 h of culture of EPCs in the presence or
absence of mCRP or pCRP. The treated EPCs were co-cultured with
HUVECs for additional 4, 16 and 24 h, respectively. The photomi-
crographs show the results of a representative experiment. The length
of the tubuli was assessed after 16 h. The box plot represents the mean
(dotted line), median (solid line) and SD of three independent
experiments
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123vein endothelial cells was determined using a Matrigel
TM
assay. Tube formation occurred at 4 h of incubation on
Matrigel
TM and was maximal at 16 h of incubation (PBS-
panel, Fig. 2c). After 24 h, the tube network started to
break up, and this was facilitated when pCRP-treated EPCs
were used (Fig. 2c). Neither mCRP nor pCRP affected the
number of tubuli or branching points. However, the length
of the tubuli was slightly increased by EPCs treated with
Fig. 3 a Principal component analysis (PCA) of the source of
variation in the sample gene expression. This was an exploratory
multivariate statistical technique that was used to simplify the
complex microarray changes that occur in three individuals (patient
10, 18 and 20) and in response to different valency CRP. This is done
by reducing the dimensionality of the data matrix by ﬁnding r new
variables (that sum the expression of multiple genes into single axes);
shown here are the average signal of each sample along the three-
dimensional virtual space of the ﬁrst three principal components. The
plot clearly shows that the variation in gene expression is dominated
by the CRP treatment and not the patient source. b Hierarchical
clustering of the gene expression response to CRP valency; 320
differentially expressed genes are plotted according to their degree of
respective co-expression. Columns represent samples, while rows
represent genes. The treatment of each sample is listed at the bottom.
The degree of correlation between genes (left) or samples (top)i s
plotted in a tree view fashion
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123Table 1 Genes up- and down-regulated in EPCs treated with mCRP (1 lg/ml)
Gene symbol Gene name mCRP treatment pCRP treatment
Fold change p Value Fold change p Value
Up-regulated genes
IFI44L Interferon-induced protein 44-like 10.04 0.001 -2.36 0.61
MX1 Myxovirus (inﬂuenza virus) resistance 1 7.58 0.008 -2.68 0.46
OAS2 20-50-Oligoadenylate synthetase 2, 69/71kDA 6.84 0.001 -2.56 0.31
LY6E Lymphocyte antigen 6 complex, locus E 6.18 0.003 -2.64 0.33
IFI27 Interferon, alpha-inducible protein 27 6.11 0.040 -2.52 0.63
IFI44 Interferon-induced protein 44 6.05 0.0005 -2.43 0.35
IFI6 Interferon, alpha-inducible protein 6 5.09 0.0004 -2.51 0.20
EPSTI1 Epithelial stromal interaction 1 (breast) 4.94 0.026 -2.06 0.94
OAS3 20-50-Oligoadenylate synthetase 3, 100 kDa 4.28 0.005 -2.90 0.10
IFIT3 Interferon-induced protein with tetratricopeptide repeats 3 3.87 0.048 -2.92 0.22
SAMD9L Sterile alpha motif domain containing 9-like 3.73 0.002 -3.04 0.02
GLTPD2 Glycolipid transfer protein domain containing 2 3.65 0.009 -2.02 0.96
EIF2AK2 Eukaryotic translation initiation factor 2-alpha kinase 2 3.42 0.007 -2.14 0.65
DDX60 DEAD (Asp–Glu–Ala–Asp) box polypeptide 60 3.28 0.031 -2.24 0.57
SPINT4 Serine peptidase inhibitor, Kunitz type 4 3.23 0.026 -2.18 0.64
IRF7 Interferon-regulatory factor 7 3.14 0.032 -2.22 0.57
PARP9 Poly (ADP-ribose) polymerase family, member 9 3.10 0.031 -2.69 0.12
GPR87 G protein-coupled receptor 87 3.08 0.017 -2.09 0.77
RETSAT Retinol saturase (all-trans-retinol 13, 14-reductase) 3.08 0.022 -2.30 0.38
CLDN4 Claudin 4 3.04 0.032 -2.27 0.46
IRF9 Interferon-regulatory factor 9 3.01 0.032 -2.53 0.18
OASL 20-50-Oligoadenylate synthetase-like 2.97 0.038 -2.46 0.23
PARP12 Poly (ADP-ribose) polymerase family, member 12 2.88 0.037 -2.50 0.17
STAT1 Signal transducer and activator of transcription 1 2.87 0.009 -2.29 0.24
HIST1H2AK Histone cluster 1, H2ak 2.85 0.039 -2.25 0.43
PEX11A Peroxisomal biogenesis factor 11 alpha 2.75 0.014 -2.50 0.06
POMT2 Protein-O-mannosyltransferase 2 2.61 0.003 -2.43 0.09
EPB41 Erythrocyte membrane protein band 4.1 2.56 0.014 -2.37 0.07
Down-regulated genes
MLLT3 Myeloid/lymphoid or mixed-lineage leukaemia; translocated to, 3 -3.48 0.007 2.08 0.80
SOX1 SRY (sex determining region Y)-box 1 -3.25 0.002 2.04 0.86
SRD5A2 Steroid-5-alpha-reductase, alpha polypeptide 2 -3.16 0.008 2.55 0.10
ACSM1 Acyl-CoA synthetase medium-chain family member 1 -3.16 0.003 2.28 0.27
RNF133 Ring ﬁnger protein 133 -3.02 0.035 2.16 0.64
ROR1 Receptor tyrosine kinase-like orphan receptor 1 -2.99 0.032 2.03 0.92
ZEB1 Zinc ﬁnger E-box-binding homoeobox 1 -2.99 0.001 2.02 0.91
ZNF300 Zinc ﬁnger protein 300 -2.96 0.011 2.12 0.64
PRAMEF21 PRAME family member 21 -2.93 0.038 2.37 0.30
SRD5A3 Steroid 5 alpha-reductase-3 -2.87 0.024 2.26 0.37
RPL21 Ribosomal protein L21 -2.64 0.008 2.41 0.05
CARD18 Caspase recruitment domain family, member 18 -2.60 0.025 2.33 0.15
PCDHGB6 Protocadherin gamma subfamily B, 6 -2.50 0.021 2.57 0.01
GRIN1 Glutamate receptor, ionotropic -2.42 0.008 2.49 0.004
Up- and down-regulated genes by mCRP (n = 3) compared to PBS-treated control EPCs were selected based on a Bayesian ‘‘volcano plot’’ of
expression with a fold change in expression level greater than twofold, and a p value\0.05 as determined by student’s t test
The fold change effect of pCRP treatment, as compared to PBS-treated control EPCs, for the differentially expressed genes was also determined
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123Table 2 Genes up- and down-regulated in EPCs treated with pCRP (5 lg/ml)
Gene symbol Gene name mCRP treatment pCRP treatment
Fold change p Value Fold change p Value
Up-regulated genes
MFAP4 Microﬁbrillar-associated protein 4 3.60 0.0010 -2.03 0.855
RABGGTB Rab geranylgeranyltransferase, beta subunit 3.51 0.0013 -2.05 0.793
FAM116B Family with sequence similarity 116, member B 3.16 0.0040 -2.00 0.994
DDIT3 DNA damage-inducible transcript 3 3.08 0.0004 -2.07 0.578
PROK2 Prokinectin 2 3.08 0.0486 -2.13 0.690
RPL7A Ribosomal protein L7a 3.05 0.0311 -2.43 0.215
PABPC4 Poly(A)-binding protein, cytoplasmic 4 (inducible form) 3.04 0.0042 -2.07 0.704
CELSR1 Cadherin, EGF LAG seven-pass G-type receptor 1 3.01 0.0104 -2.12 0.570
FRMD7 FERM domain containing 7 3.01 0.0499 -2.10 0.739
ZNF695 Zinc ﬁnger protein 695 3.00 0.0199 -2.04 0.859
HERC2 Hect domain and RLD2 2.99 0.0286 -2.00 0.998
RPL13L Ribosomal protein L13 pseudogene 5 2.98 0.0094 -2.12 0.566
ZNF277 Zinc ﬁnger protein 277 2.96 0.0002 -2.11 0.325
LRAT Lectin retinol acyltransferase 2.90 0.0157 -2.12 0.572
STAG3L4 Stromal antigen 3-like 4 2.87 0.0329 -2.25 0.368
ABHD14B Abhydrolase domain containing 14B 2.86 0.0488 -2.17 0.554
AVPI1 Arginine vasopressin-induced 1 2.85 0.0062 -2.21 0.258
DYM Dymeclin 2.82 0.0005 -2.05 0.652
ROM1 Retinal outer segment membrane protein 1 2.81 0.0099 -2.30 0.163
RAC3 ras-related C3 botulinum toxin substrate 3 2.81 0.0076 -2.10 0.558
CCDC104 Coiled-coil domain containing 104 2.81 0.0002 -2.15 0.164
SLC16A10 Solute carrier family 16, member 10 2.80 0.0082 -2.15 0.398
PHACTR1 Phosphatase and actin regulator 1 2.80 0.0079 -2.04 0.813
PCOLCE2 Procollagen C-endopeptidase enhancer 2 2.76 0.0379 -2.10 0.657
ZNF581 Zinc ﬁnger protein 581 2.75 0.0207 -2.11 0.602
CRP C-reactive protein, pentraxin related 2.72 0.0400 -2.15 0.528
SIRPG Signal-regulatory protein gamma 2.70 0.0129 -2.24 0.210
NNMT Nicotinamide N-methyltransferase 2.70 0.0115 -2.07 0.685
EIF2A Eukaryotic translation initiation factor 2A 2.69 0.0134 -2.22 0.249
FABP2 Fatty acid-binding protein 2, intestinal 2.69 0.0067 -2.13 0.411
RGMA RGM domain family, member A 2.69 0.0146 -2.08 0.636
POLR1E Polymerase (RNA) polypeptide E, 53 kDa 2.61 0.0358 -2.18 0.385
LETMD1 LETM1 domain containing 1 2.60 0.0168 -2.20 0.258
FTHL11 Ferritin, heavy polypeptide-like 11 2.59 0.0422 -2.25 0.261
CSNK2A2 Casein kinase 2, alpha prime polypeptide 2.57 0.0036 -2.27 0.061
CCDC140 Coiled-coil domain containing 140 2.53 0.0332 -2.17 0.346
PAX7 Paired box 7 2.49 0.0343 -2.25 0.190
ZFAND1 Zinc ﬁnger, AN 1-type domain 1 2.49 0.0175 -2.21 0.175
RAB39 RAB39, member RAS oncogene family 2.44 0.0350 -2.25 0.156
PCDHGB6 Protocadherin gamma subfamily B, 6 2.44 0.0115 -2.38 0.021
GRIN1 Glutamate receptor, inotropic, N-methyl D-aspartate 1 2.37 0.0041 -2.31 0.008
RPL21 Ribosomal protein L21 2.30 0.0474 -2.49 0.008
Down-regulated genes
ABCA13 ATP-binding cassette, sub-family A (ABC1), member 13 -5.39 0.0009 2.02 0.931
LTF Lactotransferrin -5.11 0.0427 2.27 0.652
PDAP1 PDGFA associated protein 1 -5.04 0.0005 2.23 0.353
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123mCRP, whereas the ability of these cells to support tube
formation was signiﬁcantly reduced after treatment with
pCRP, respectively (p\0.001, Fig. 2c).
Differential effect of mCRP and pCRP on the gene
expression proﬁle of EPCs
RNA for whole-genome gene expression analysis was
extracted after a 72-h culture period of in vitro expanded
cord blood-derived CD34
? cells on ﬁbronectin-coated
dishes. Cells were treated with mCRP (1 lg/ml), pCRP
(5 lg/ml) or PBS in EGM-2. In addition, RNA was
extracted before the 72-h culture period to determine the
background of differentially expressedgenes induced by the
EPC differentiation process during the 72-h culture period
on ﬁbronectin-coated dishes. The microarray analysis was
undertaken in three biological repeats (three different cord
blood donors) on beadchips containing [48,000 different
probes. Box and whisker plots conﬁrmed that the normali-
sation of the arrays achieved comparable dynamic range of
the different samples (supplementary Fig. 1). In contrast,
principal component analysis (PCA) demonstrated that the
gene expression, induced by either mCRP or pCRP, was
systematically distinct across the three donors (Fig. 3a).
Hierarchical clustering of 320 differentially expressed
genes further demonstrated that mCRP and pCRP treatment
differentially induced coordinate programmatic gene
expression and differentiation (Fig. 3b).
The gene expression analysis comparing EPCs treated
with mCRP to EPCs treated with PBS detected 42 dif-
ferentially expressed genes, of which 28 were signiﬁ-
cantly up-regulated and 14 were down-regulated (at least
twofold change, p\0.05) (Table 1). Comparing
expression patterns of EPCs treated with pCRP to PBS-
treated EPCs detected 86 differentially expressed genes,
of which 42 were up-regulated and 44 were down-regu-
lated (at least twofold change, p\0.05) (Table 2). As
demonstrated in Table 1, analysis of the differentially
expressed genes revealed that mCRP and pCRP showed
opposing effects, meaning that the genes up-regulated by
mCRP were down-regulated by pCRP, and vice versa.
mCRP, but not pCRP, stimulates the expression
of interferon-a responsive genes
To benchmark differential gene expression in EPCs in
response to either mCRP or pCRP treatment to existing
microarray literature and to gain more biological insight
from the gene expression pattern speciﬁc for mCRP and
pCRP treatment, we have employed Ingenuity Pathway
Analysis
 (IPA) and Gene Set Enrichment Analysis [41].
Those genes that were up-regulated in response to mCRP
exhibited extensive cross interactions, centred around
interferon-a (Table 1; Fig. 4). Treatment with pCRP led
to a highly different response in the gene expression
proﬁle centred around the MAPK pathway, DDIT3/
GADD153 and consequent cell growth (ribosomal sub-
units), and cell cycle regulators such as p21/CDKN1A
(Table 2, Fig. 5). Genes with signiﬁcant down-regulation
in response to mCRP and pCRP treatments are described
in Tables 1 and 2. An IPA network analysis of selected
down-regulated genes in response to mCRP and pCRP,
respectively, is depicted in Supplementary Figures 2
and 3.
The gene expression was veriﬁed by quantitative real-
time PCR with RNA isolated from mCRP (1 lg/ml),
Table 2 continued
Gene symbol Gene name mCRP treatment pCRP treatment
Fold change p Value Fold change p Value
IFIT1 Interferon-induced protein with tetratricopeptide repeats 1 -4.39 0.0264 2.86 0.175
TXNIP Thioredoxin-interacting protein -3.75 0.0207 2.03 0.917
UGT1A3 UDP glucoronsyltransferase 1 family, polypeptide A3 -3.60 0.0453 2.05 0.891
RIMS3 Regulating synaptic membrane exocytosis 3 -3.47 0.0004 2.04 0.906
PKD2L1 Polycystic kidney disease 2-like 1 -3.47 0.0191 2.34 0.336
MT1L Metallothionein 1L (gene/pseudogene) -3.37 0.0006 2.07 0.666
OXTR Oxytocin receptor -3.30 0.0464 2.04 0.906
SIGLEC5 Sialic acid-binding Ig-like lectin 5 -3.29 0.0350 2.03 0.912
NCF1 Neutrophil cytosolic factor 1 -3.25 0.0308 2.00 0.987
LRRC39 Leucin rich repeat containing 39 -3.20 0.0082 2.14 0.549
Up- and down-regulated genes by pCRP (n = 3) compared to PBS-treated control EPCs were selected based on a Bayesian ‘‘volcano plot’’ of
expression with a fold change in expression level greater than twofold, and a p value\0.05 as determined by student’s t test
The fold change effect of mCRP treatment, as compared to PBS-treated control EPCs, for the differentially expressed genes was also determined
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123pCRP (5 lg/ml) or PBS-treated EPCs and expressed as
fold change in gene expression compared to the
PBS-treated control (Fig. 6). Conﬁrming the results of
the gene array, IFI44L was the most up-regulated gene in
response to mCRP treatment (29.3-fold ± 17) followed
by MX1 (8.3-fold ± 2.2) and OAS2 (8.6 ± 2.4) (Fig. 6).
Treatment with pCRP but not mCRP led to increased
expression of DDIT3 (4.4 ± 0.97) and PROK2
(2.2 ± 0.86) (Fig. 6).
The effects of IFNa2A on phenotypic and functional
characteristics of EPCs
The percentage of EPCs double positive for the uptake of
AcLDL and binding of ulex lectin was signiﬁcantly higher
(p\0.001) in the presence of IFNa2A or mCRP compared
to pCRP (Fig. 7a). Also, compared to pCRP-treated EPCs,
IFNa2A or mCRP-treated EPCs gave rise to signiﬁcantly
fewer colonies (p\0.01) (Fig. 7b). Compared to PBS,
mCRP or IFNa2A-treated EPCs, pCRP-treated EPCs
showed a reduced ability to stimulate endothelial tube
formation assessed by the length of endothelial tubes in a
Matrigel
TM assay with HUVECs (Fig. 7c).
Discussion
This study aimed to assess the effects of pentameric
(p)CRP and monomeric (m)CRP on function and differ-
entiation of EPCs. The generation of mCRP by dissociation
of pCRP on the cell membrane of activated platelets has
been recently described as a pathophysiological mecha-
nism to localise inﬂammatory reactions, e.g. at developing
atherosclerotic plaques [15]. The regenerative capability
and the numbers of circulating EPCs have been associated
with atherosclerotic plaque development and thus we
hypothesised that CRP, particularly mCRP, is a potential
regulator of EPC function.
The two major ﬁndings of this study are: (1) mCRP and
pCRP at concentrations similar to the reported serum levels
of CRP in patients with atherosclerotic disease [2] induce an
opposing gene expression proﬁle in cord blood-derived
EPCsaswellasdifferentialeffectsonthefunctionalcapacity
of EPCs. (2) The highly up-regulated genes in response to
mCRPbutnottopCRPtreatmentarecentredaroundthepro-
inﬂammatoryactionsofinterferon-aandarehighlyrelatedto
up-regulated genes in patients with systemic lupus ery-
thematodes (SLE). Interferon-a2A treatment induced a
functional response in EPCs similar to mCRP treatment.
Fig. 4 Ingenuity pathways
analysis. Network of up-
regulated genes in response to
1 lg/ml mCRP. Networks of
gene/gene product interaction
were generated using IPA
(Ingenuity
 Systems,
http://www.ingenuity.com).
Genes or gene products are
represented as nodes, and the
biological relationship between
two nodes is represented as an
edge (line). All edges are sup-
ported by at least one published
reference. Solid edges represent
a direct relationship and dashed
edges represent an indirect
relationship. The red node col-
our represents up-regulation in
response to mCRP and the col-
our intensity indicates the
degree of up-regulation. The
shape of each node represents
the functional class of the gene
product, as shown in the legend
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123Differential effects of mCRP and pCRP on monocyte
and platelet function have been observed in previous
studies of our group and others [15, 16, 40]. EPC function
following pCRP treatment has been extensively examined
in previous studies [7, 19, 38, 64], but the differential
effects of CRP isoforms on EPCs have not been investi-
gated yet. EPCs are thought to play a key role in the
regeneration of injured/inﬂamed endothelium, and
reduced functional capacity of EPCs has been correlated
to serum levels of CRP [9]. Therefore, CRP (either
monomeric or pentameric) may directly account for the
impaired EPC function in patients with chronically ele-
vated serum CRP levels in atherosclerotic disease. Our in
vitro study conﬁrms the results of previous studies
showing decreased viability and induction of apoptosis
with pCRP concentrations [10 lg/ml [5, 19, 52, 64].
Furthermore, we are able to conﬁrm that pCRP, but not
mCRP, decreases the number of cells double positive for
the uptake of AcLDL and the binding of ulex lectin,
which has been described as a common EPC phenotype
[24, 29, 48, 69]. The ability of EPCs to stimulate endo-
thelial tube formation in co-cultures with HUVECs has
been used to describe the pro-angiogenic functions of
EPCs [8, 24, 64]. In line with other reports [64], our
results indicate that pCRP directly impairs endothelial
tube formation and this occurred at the concentration of
5 lg/ml, which was not cytotoxic to the EPCs, thereby
indicating that EPC differentiation rather than viability in
response to pCRP treatment impaired the ability of EPCs
to support endothelial tube formation. This interpretation
is supported by the decreased number of AcLDL and ulex
lectin double-positive cells after pCRP treatment and the
signiﬁcant increase in the number of CFU in response to
pCRP treatment.
The increase in CFUs may be explained by the up-regu-
lation of two genes (DDIT3 and PROK2) in response to
pCRP treatment. PROK2 has been shown to increase the
number of CFUs and to enhance progenitor cell mobilisa-
tion [36] and DDIT3 (also known as GADD153 or CHOP),
although also associated with the response to oxidative
stress [12, 42], increased the number of CFUs in erythroid
cells [10]. Interestingly, pCRP treatment of human coro-
nary vascular smooth muscle cells with 5 lg/ml of pCRP
also led to a [2-fold increase in expression of DDIT3
(GADD153) [5], which has been reproduced by others with
higher concentrations of pCRP (25 lg/ml) [52].
Fig. 5 Ingenuity pathways
analysis. Network of
up-regulated genes in response
to 5 lg/ml pCRP. Networks
of gene/gene product interaction
were generated using IPA
(Ingenuity
 Systems,
http://www.ingenuity.com).
Genes or gene products are
represented as nodes, and the
biological relationship between
two nodes is represented as an
edge (line). All edges are sup-
ported by at least one published
reference. Solid edges represent
a direct relationship and dashed
edges represent an indirect
relationship. The red node col-
our represents up-regulation in
response to pCRP. The shape of
each node represents the func-
tional class of the gene product,
as shown in the legend of Fig. 4
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with low concentrations of pCRP and decreased viability
and increased apoptosis with higher concentrations, we
hypothesise that moderately elevated levels of pCRP under
non-inﬂammatory conditions may have a different impact
on EPC differentiation and function as compared to
inﬂammatory conditions. This is supported by the obser-
vation that the endothelial colony forming capacity of
EPCs is positively correlated to pCRP levels in healthy
volunteers [9]. Whereas under inﬂammatory conditions,
such as those present in atherosclerotic disease, localised
dissociation of pCRP to mCRP may occur [15]. This in turn
could then have a negative biological effect on EPC
numbers and function as observed in patients with ath-
erosclerosis [55, 67, 68].
In our in vitro study, mCRP treatment of EPCs did not
decrease the numbers of AcLDL and ulex lectin positive
cells and there was also no decrease in their capacity to
support endothelial tube formation with mCRP treatment,
which furher highlights the differential effects of the two
CRP isoforms that has been shown in vitro in various cell
types [28, 32–35, 56, 72]. We compared the concentrations
of 1 lM mCRP with 5 lM pCRP to account for the dif-
ferences in molarity between pCRP (115 kDa) and mCRP
(23 kDa).
The substantial differences in the effects of mCRP and
pCRP were conﬁrmed in whole-genome gene expression
analysis. The genes up-regulated by mCRP are known to be
responsive to the pro-inﬂammatory interferon-a. Among
the 28 highly up-regulated genes in response to mCRP
treatment were nine interferon-inducible genes (IFI44L,
MX1, IFI27, OAS3, IFI44, Ly6E, EPISTI1, STAT1).
Interestingly, these genes matched highly up-regulated
genes described in the microarray analysis of tissue from
synovial biopsies of patients with systemic lupus erythe-
matosus [44]. In addition, the three genes that showed the
strongest up-regulation in response to mCRP (IFI44L,
MX1 and OAS2) were also found to be the most up-regu-
lated genes in peripheral blood mononuclear cells
(PBMCs) of paediatric patients with SLE [4]. Importantly,
patients with SLE are more prone to the development of
atherosclerosis [57] and especially women with SLE and
coronary artery disease (CAD) have a poor outcome after
percutaneous coronary intervention (PCI) [39]. Interferon-a
(measured via expression of the interferon-a responsive
genes IFI44 and MX1) has been linked to abnormal vas-
cular repair caused by EPC dysfunction in patients with
SLE thereby generating the hypothesis that interferon-a
triggered EPC dysfunction is involved in the accelerated
atherosclerosis in patients with SLE [11, 30]. This is sup-
ported by the observation that increased expression of MX1
in PBMCs of SLE patients and elevated levels of pCRP are
independently associated with EPC dysfunction [37]. Fur-
thermore, impaired function of EPCs was accompanied by
increased expression of MX1 in an animal model of SLE
[60]. Finally, auto-antibodies against mCRP have been
described in serum from patients with active SLE [59],
which generates the hypothesis that elevated mCRP levels
lead to interferon-a-mediated impairment of EPCs in
patients with SLE, thereby impairing vascular repair and
accelerating the development of atherosclerosis. Of note,
our data do not directly demonstrate a pro-atherosclerotic
effect of mCRP. However, for interferon-a and b, such a
direct pro-atherosclerotic effect has very recently been
demonstrated in mouse models of atherosclerosis [21, 43].
Most interestingly, up-regulation of MX1, OAS1, OAS2
and IFIT3 mRNA in ruptured atherosclerotic plaques in
human carotid arteries has been found [21].
By conﬁrming the fundamentally different pathological
functions of mCRP and pCRP, our ﬁndings may help to
explain the clinical situation in vivo. The positive impact of
pCRP on endothelial colony forming capacity of EPCs
observed by us has also been described in healthy volun-
teers [9]. Under inﬂammatory conditions, such as athero-
sclerosis, pCRP is dissociated to mCRP [15] and thus
exerts substantially different functions, potentially fuelling
the inﬂammatory response, as suggested by the results of
our whole-genome gene expression analysis that suggests
pro-inﬂammatory properties for mCRP. The localised dis-
sociation of pCRP to mCRP in inﬂammation could
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of selected highly differentially expressed genes 
fold change in gene expression
Fig. 6 Validation of the expression of selected highly upregulated
genes in mCRP (1 lg/ml) and pCRP (5 lg/ml)-treated EPCs by
quantitative real-time PCR. Validation of gene expression by
quantitative real-time PCR. The mean in gene expression from EPCs
derived from three individual cord blood donors was obtained using
differences in cycle threshold between the gene and 18 s (DCt). The
fold change in difference (DDCt) in gene expression in the treated
samples compared to the PBS control samples was determined
(2DDCt) and expressed in the diagram as mean and SEM of n = 3.
Grey bars represent pCRP and black bars represent mCRP-treated
EPCs
Basic Res Cardiol (2011) 106:879–895 891
123potentially mediate the negative biological effect on EPC
numbers and function observed in patients with athero-
sclerosis [55, 67, 68].
Our study focussed on the in vitro effects of two iso-
forms of CRP on cord blood-derived EPCs to explore the
functional, phenotypical and gene expression proﬁles of
monomeric and pentameric CRP towards a rare cell popu-
lation with potent pro-angiogenic capabilities involved in
the natural repair of vascular damage. A limitation of our
study is that the results obtained in our in vitro system
cannot directly be translated into in vivo situation where a
more complex system of different vascular cells acts in
concert to maintain the vascular integrity, and each cell
type may have a different response to the two isoforms of
CRP. Furthermore, the use of cord blood-derived cells may
bear the risk of a differential response in gene expression in
comparison to adult EPCs. However, most of the functional
properties of cord blood-derived EPCs resemble those of
EPCs derived from adult donors, and EPCs derived from
both young and old donors have successfully been used in
the past to treat cardiovascular disease in animal models
and human subjects [25, 46, 54, 70]. Interestingly, a recent
report describes a weaker speciﬁc interferon-a-mediated
immune response in cord blood-derived mononuclear cells
as compared to mononuclear cells from adult donors [65].
Therefore, our gene expression analysis could also under-
estimate the pro-inﬂammatory effects of mCRP.
In conclusion, we provide evidence for a differential,
highly opposing effect of monomeric and pentameric
C-reactive protein on human umbilical cord blood-derived
EPCs. Monomeric CRP induced the up-regulation of pro-
inﬂammatory, interferon-responsive genes in EPCs,
whereas pentameric CRP exhibited a primarily non-
inﬂammatory gene response. These data support the con-
cept that localised mCRP generation thus provides a
means to locally regulate EPC function in vascular
homoeostasis.
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Fig. 7 The effect of mCRP (1 mg/ml), pCRP (5 mg/ml) or IFNa2A
(1 ng/ml) on phenotype and function of EPCs. a Binding of ulex
lectin and uptake of acetylated LDL after 72 h of culture of EPCs in
the presence or absence of pCRP, mCRP and IFNa2A. The bar graph
shows the percentage of cells double positive for binding of ulex
lectin and uptake of acetylated LDL as compared to the total number
of cells in three random optical ﬁelds (209 magniﬁcation). Mean and
SD of n = 3. The statistical signiﬁcance was determined by one-way
ANOVA with Tukey’s post hoc test, ***p\0.001. b The bar graph
shows the number of colony forming units (CFU-Hills) visualised by
Giemsa staining, formed by EPCs that had been cultured in the
presence of pCRP, mCRP or IFNalpha2 for 72 h (mean and SD of
three individual donors, n = 3). The statistical signiﬁcance was
determined by one-way ANOVA with Tukey’s post hoc test,
**p\0.01. c The box plot shows the lengths of the tubuli formed
in a co-culture of HUVECs and EPCs (n = 3) in an endothelial tube
formation assay. The EPCs had been cultured in the presence of
pCRP, mCRP or IFNa2A for 72 h prior to the assay. The photomi-
crographs were taken when a clear tubuli network was observed after
16 h of incubation. The statistical signiﬁcance was determined by
ANOVA on ranks with Dunn’s post hoc test, *p\0.05
b
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